Skip to main content
Log in

Synthesis, development and preclinical study of EDDA based 99mTc-5-fluorouracil for brain imaging

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

5-Fluorouracil is used as an antineoplastic agent in solid tumors. The study was conducted to analyze the effect of EDDA on synthesis of 5-fluorouracil with 99mTc. The 99mTc-5-flurouracil was formulated using stannous agent, and EDDA. This complex was stable for 4 h, with post labeling efficiency of 92 %. The distribution study in animal model showed that after 30 min 35 ± 8 % of injected dose cross the blood brain barrier and excreted through kidney with no sign of toxicity. It was concluded that the addition of EDDA modified the labeling side in 5-fluorouracil for 99mTc, which localized in brain and hence can be used further for brain imaging study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Graph 1
Graph 2

Similar content being viewed by others

References

  1. Moritz FK, Adam Z, Jesse VJ, Cristina LZ, Paul JK, Erik M, Ken P, Ruimin H, Carl C, Frezghi H, Robert S, Cameron WB, Ingo KM, Eric CH, Sanjiv SG (2012) A brain tumor molecular imaging strategy using a new triple-modality MRI-Photoacoustic-Raman nanoparticle. Nat Med 18(5):829–834

    Article  Google Scholar 

  2. Committee on State of the Science of Nuclear Medicine, National Research Council (2007) Advancing nuclear medicine through innovation. The National Academies Press, ISBN: 0-309-11068-8

  3. Filippi L, Santoni R, Manni C, Danieli R, Floris R, Schillaci O (2005) Imaging primary brain tumors by single-photon emission computerized tomography (SPECT) with Technetium-99m Sestamibi (MIBI) and Tetrofosmin. Curr Med Imaging Rev 1(1):61–66

    Article  CAS  Google Scholar 

  4. Garcia V, Garcia JM, Pena C, Silva J, Dominguez G, Hurtado A, Alonso I, Rodriguez R, Provencio M, Bonilla F (2006) Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin Cancer Res 12(7):2095–2100

    Article  CAS  Google Scholar 

  5. Okarvi SM, Jammaz AL (2010) Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors. Nucl Med Biol 37(3):277–288

    Article  CAS  Google Scholar 

  6. Faheem AR, Bokhari TH, Roohi S, Mushtaq A, Sohaib M (2013) 99mTc-Daunorubicin a potential brain imaging and theranostic agent: synthesis, quality control, characterization, biodistribution and scintigraphy. Nucl Med Biol 40:148–152

    Article  CAS  Google Scholar 

  7. Hina S, Roohi S, Rajoka MI, Haque A, Bokhari TH, Sohaib M (2015) Preparation, quality control and biological characterization of 99mTc-vincristine. J Radioanal Nucl Chem 304(2):553–561

    Article  CAS  Google Scholar 

  8. Ume KD, Irfan UK, Javed M, Ali M, Waqar SH, Sohail M, Jamil A (2013) Development of 99mTc-5-fluorouracil as a potential tumor diagnostic agent. Pak J Pharm Sci 26(2):333–337

    Google Scholar 

  9. Liu S (2004) The role of coordination chemistry in the development of target specific radiopharmaceuticals. J Chem Soc 33:445–461

    CAS  Google Scholar 

  10. Rashid R, Javed M, Fayyaz A, Asima S, Sohail M, Misbah M, Shahid R, Saqib R (2013) Preparation of 99mTc-labeled methotrexate by a direct labeling technique as a potential diagnostic agent for breast cancer and preliminary clinical results. Hell J Nucl Med 16(1):33–37

    Google Scholar 

  11. Terence JB, Benjamin HB, Brian PM, Elson LS, Mary FH, Michael KC, Joseph H, Clifford RJ (1999) Comparative study of 99mTc-ECD and 99mTc-HMPAO for peri-ictal SPECT: qualitative and quantitative analysis. J Neurol Neurosurg Psychiatry 66:331–339

    Article  Google Scholar 

  12. Kung HF (2001) Development of 99mTc labeled tropanes: TRODAT-1, as a dopamine transporter imaging agent. Nucl Med Biol 28(5):505–508

    Article  CAS  Google Scholar 

  13. Johannsen B, Pietzsch HJ (2002) Development of technetium-99m-based CNS receptor ligands: have there been any advances? Eur J Nucl Med Mol Imaging 29(2):263–275

    Article  Google Scholar 

  14. Ralf S, Vadim BG, Andrew R, Jean P, Soucy Esther S, Björn W, Carmen W (2013) Design of brain imaging agents for positron emission tomography: do large bioconjugates provide an opportunity for in vivo brain imaging? Future Med Chem. doi:10.4155/fmc.13.128

    Google Scholar 

  15. Gilman AG, Ral TW, Nies AS, Taylor P (1990) The pharmacological basis of therapeutics. Pergamon Press, New York

    Google Scholar 

  16. Rockville (2010) United States Pharmacopeia Convention, (2): 2874–2875

  17. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 6(4):215–237

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N. Ahmed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmed, N., Saeed, A.M., Fatima, S. et al. Synthesis, development and preclinical study of EDDA based 99mTc-5-fluorouracil for brain imaging. J Radioanal Nucl Chem 309, 805–811 (2016). https://doi.org/10.1007/s10967-015-4690-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-015-4690-4

Keywords

Navigation